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Subtypes, defined by variation in the outer membrane
protein PorA, are an integral part of the characterization
scheme for Neisseria meningitidis. Identification of these
variants remains important as the PorA protein is a major
immunogenic component of several meningococcal vac-
cines under development, and characteristics of PorA are
used to provide detailed epidemiologic information.
Historically, serosubtypes have been defined by reactivity
with a set of monoclonal antibodies. However, nucleotide
sequence analyses of porA genes have established that
the panel of serosubtyping monoclonal antibodies is not
exhaustive, and many porA variants cannot be detected.
In addition, the nomenclature system used to define sub-
types is inadequate. We examined all available nucleotide
sequences of the porA VR1 and VR2 regions to identify
and define subtype families. A revised nomenclature
scheme, compatible with the previous serologic nomencla-
ture scheme, was devised. A Web-accessible database
describing this nomenclature and its relationship to previ-
ous schemes was established (available from: http://neis-
seria.org/nm/typing/pora).
N
eisseria meningitidis is a major cause of bacterial
meningitis and septicemia worldwide (1). In the
absence of a comprehensive vaccine against this organism,
the characterization of its variable surface antigens is
important for epidemiologic monitoring and vaccine
development (2). The serologic characterization scheme
for meningococci comprises the following: groups, based
on variants in the capsular polysaccharide; types, based on
variants of the PorB outer membrane protein (OMP); sub-
types, based on variants of the PorA OMP; and immuno-
types, based on variants in the lipooligosaccharide (3).
Within this scheme, PorA, also known as the class 1 OMP,
is assigned the prefix “P1.” followed by numbers, separat-
ed by commas, that correspond to the subtype designation
(thus: P1.7,16). The two PorA variable regions (VR1 and
VR2) that confer the subtypes are especially important
because they elicit bactericidal antibodies in humans (4).
Consequently, a number of meningococcal vaccines under
development contain the PorA protein as a major compo-
nent (5).
Nucleotide sequence analyses of porA genes from mul-
tiple meningococcal isolates have established that the
panel of serosubtyping monoclonal antibodies (MAbs) is
not comprehensive. Meningococci are frequently only par-
tially serosubtyped, and an increasing number of isolates
are classified as non-serosubtypeable, either because a
variant is not recognized by MAbs or because PorA is not
expressed. This heterogeneous group of isolates can be
fully characterized on the basis of their PorA VR1 and
VR2 amino acid sequences deduced from nucleotide
sequence data. To accommodate subtypes identified on the
basis of sequence data alone, the scheme originally devel-
oped for MAb reactivity data (3) was modified so that VR
families and variants were assigned on the basis of amino
acid sequence relationships rather than their reactivity with
specific MAbs. A distance matrix of all known VR1 and
VR2 amino acid sequences was constructed, and VR
amino acid sequences containing >80% identity to each
other were grouped into VR families. The VR epitope rec-
ognized by an existing MAb raised against PorA, or the
first defined amino acid sequence of a VR family, was
arbitrarily designated as the prototype VR for that particu-
lar family. Successive distinct members of a VR family
were designated as minor variants of that family, and as
such were sequentially assigned an additional unique
lower case letter, e.g., P1.5a, P1.5b, P1.5c (6).
Although this nomenclature system was sufficiently
flexible to accommodate both novel subtypes determined
from nucleotide sequence analyses and those defined by
the reactivity of specific MAbs, limitations have become
apparent. First, while the 80% similarity rule has general-
ly proved adequate to assign VR families, it is open to mis-
interpretation, leading to the inappropriate designation of
VR sequences. Second, the assignment of minor variants
within VR families is limited by the number of letters in
the alphabet (7,8). We present a revised nomenclature,
which addresses these issues and shows the relationship of
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through the Internet has been established, which will
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Materials and Methods
Bacterial Isolates 
Two sets of meningococcal isolates were used for porA
gene sequencing in this work. The first was a set of 393
isolates from cases of disease from diverse locations
throughout the United Kingdom. These included 125 iso-
lates from 1975; 100 isolates from 1985; 100 isolates
from1995; and 18 urethral isolates, provided by the
Meningococcal Reference Unit, Manchester Public Health
Laboratory, Manchester. Fifty isolates were provided by
the Scottish Meningococcus and Pneumococcus Reference
Laboratory, Glasgow. The second set of isolates included
the 107 globally representative isolates obtained from both
patients and carriers; these isolates were used to develop
and evaluate the multilocus sequence typing isolate char-
acterization scheme (9).
porA Gene Sequences and Validation
Nucleotide sequences of porA genes encoding the vari-
ants included in Appendix Tables 1 and 2 (online only;
available from: http://www.cdc.gov/ncidod/EID/vol10no4/
03-0247.htm_app.htm) were obtained from the literature
or GenBank, determined by sequencing of polymerase
chain reaction (PCR) products from the above isolates, or
submitted by personal communication or to the PorA Web
site. Where possible, sequences not determined in this
study were validated by requesting sequence electrophero-
grams from depositors. When electropherograms could not
be resolved, isolates were requested and the porA genes
resequenced. Seven sequences contained errors on rese-
quencing original isolates and were therefore removed
from the new nomenclature scheme. The deposited VR
sequences used in this study were those submitted to the
PorA Web site by June 11, 2001.
DNA Amplification and Nucleotide Sequence
Determination of porA
Boiled meningococcal suspensions or DNA prepared
from such suspensions with an Isoquick kit (Microprobe
Corporation, Washington) were used as template to ampli-
fy the porA gene by using Taq Polymerase (Applied
Biosystems, by Roche Molecular Systems Inc.,
Branchburg, NJ) with primers 210 and 211 (10). The
amplification products were purified by precipitation with
the addition of 0.6 V of 20% polyethylene glycol
8000/2.5M NaCl (11) and their nucleotide sequences
determined at least once on each DNA strand. Sequence
reactions were carried out with primers 8L, 8U, 103L,
103U, 122L, 122U, 210, and 211 (10) using BigDye Ready
Reaction Mix (Applied Biosystems) in accordance with
the manufacturer’s instructions. Unincorporated dye termi-
nators were removed by precipitation of the termination
products with the addition of 2.6 V of 96% ethanol and 115
mM sodium acetate. The reaction products were then sep-
arated and detected with an ABI Prism 377 automated
DNA sequencer (PE Biosystems). Sequences were assem-
bled from the resultant electropherograms with the
STADEN suite of computer programs (12).
Manipulation and Alignment of Sequences
Sequences were manipulated in SeqLab, part of the
GCG software package (13). All unique nucleotide
sequences for each VR were aligned with reference to both
the nucleotide and the amino acid sequences, such that all
sequences remained in frame, gaps were minimized, and
similar codons were aligned.
Identification of Families and Variants
To remain consistent with serologic and historical
nomenclature, where a variant had been identified previ-
ously by serologic means, the identified sequence was
used as a family prototype around which new sequences
were grouped. An 80% amino acid identity cut-off—
against the shortest sequence length when the sequences
were of different length to allow for insertions, duplica-
tions, and deletions—was used as a guide in this grouping.
In a few cases, a variant was assigned to a particular fam-
ily even though the amino acid identity was slightly less
than 80%, compared to the family prototype. In these
cases, the new variant was still more similar to this partic-
ular family than to others but also contained a particular
motif that was representative of family members.
Therefore, a combination of overall similarity and pres-
ence of particular motifs was used to make the groupings.
In a few cases, family-specific motifs were missing, but
the sequences were otherwise identical or highly similar to
members of the family. In such cases, the sequence was
assigned as a variant of the family.
To further ensure that family groupings were consis-
tent, the relationships among aligned nucleotide sequences
encoding VR1 or VR2 were visualized by split decompo-
sition analysis using SPLITSTREE version 3.1 (14). The
split decomposition analysis was carried out in a sequen-
tial manner. In each analysis, a limited number of families
were resolved, and the remaining variants were clustered
together at a node. The variants that were resolved first
were removed, and the analysis was repeated to resolve
further families, and so on until all family groups were
resolved (15). For analysis of the whole datasets,
Hamming distances (equivalent to p-distance) were used
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Meningococcal PorA Variable Regionsbecause some of the families were so diverse that using a
substitution model was not possible. This method resolved
the most distantly related families. The Kimura three
parameter model (16) was used to determine whether relat-
ed sequences constituted families.
A database and Web site containing all the assignments
have been established (available from: http://neisseria.
org/nm/typing/pora). The sequences are stored in a
PostgreSQLdatabase running on Linux. Perl scripts enable
the database to be queried against either peptide or
nucleotide sequences; when an identical match is not
found, a BLAST search (17) can be performed to identify
the nearest variant and family. Any length of sequence can
be queried, enabling the variants to be quickly identified
from a whole or partial gene sequence.
Results
Validation of Sequence Variants
The sequences defining the following subtypes in the
previous nomenclature were not included in the new
nomenclature as a consequence of the sequence validation:
P1.2a, P1.2d, P1.5b, P1.10h, P1.10i, P1.10j, P1.18b,
P1.19c, P1.24, P1.29.
Resolution of VR Families
The amino acid sequences of the prototype member of
each of the VR families identified are shown aligned in
Figures 1 and 2 together with corresponding nucleotide
sequences. A total of 10 VR1 and 17 VR2 families were
resolved. The most closely related VR families are VR2
P1.2 and VR2 P1.10, although the family prototypes are
recognized by specific MAbs that are not cross-reactive.
Both families start with a consensus amino acid sequence
of HFVQ and end with PTLVP. They can be differentiated,
however, by split decomposition where they cluster sepa-
rately (15) and by certain motifs in their sequences. The
P1.10 family members have a consensus motif QNKQNQ,
with either the first or second triplet commonly repeated,
while the P1.2 family members usually start with HFVQQ
and commonly have variations of PQSQ or PKSQ.
Grouped within the P1.2 family are four sequences that
were previously designated as the P1.33 family. Like
sequences in most of the P1.2 family members, these start
with HFVQQ and, although they mostly end with
SKPTLVP rather than SQPTLVP, they maintain the posi-
tion of the serine residue.
Variation within Families
There was more variation within VR2 (161 unique vari-
ants) than in VR1 (73 unique variants). The variation in the
VR families was mainly due to changes that could be
ascribed to single nonsynonymous base changes. Although
there may be minor differences in the relative contribution
of nonsynonymous base changes and insertions or dele-
tions between individual VR families, approximately twice
as many variants have arisen as a result of point mutations
than from any other type of mutation. The repetition of
amino acid motifs or single residues was common within
VR2. An example is the repetition of a threonine residue
within the VR2 P1.13 family, where there are sequences
with three to nine consecutive threonine residues.
Nomenclature Scheme
A consultation process was conducted by email among
users of the PorA Web site and other interested parties.
Several formats for a revised nomenclature were proposed
and a request for alternatives made. The consensus opinion
was to replace letters with numbers in subtype variant
names in the following format: the prefix "P1." followed
by the VR1 family name, followed by a dash and then the
variant number, followed by a comma and the VR2 variant
name in the same format. When a family prototype VR, or
first sequence belonging to a family, was identified, no
variant number was used; for example, a protein with VR1
676 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 4, April 2004
RESEARCH
Figure 1. Alignment of the amino acid and corresponding
nucleotide sequence of each VR1 family “prototype.” For a larger
reproduction of this figure, see http://www.cdc.gov/ncidod/EID/
vol10no4/03-0247-G1.htm
Figure 2. Alignment of the amino acid and corresponding
nucleotide sequence of each VR2 family “prototype.”  For a larger
reproduction of this figure, see http://www.cdc.gov/ncidod/EID/
vol10no4/03-0247-G2.htmfamily 5 variant 3, and VR2 family 10 prototype would be
written as: P1.5–3,10. This scheme was then used to
rename all of the variants examined. The new names of
variants are listed in online Appendix Tables 1 and 2,
together with the previous nomenclature, peptide
sequence, and source or reference. A database accessible
through the Internet was established (available from:
http://neisseria.org/nm/typing/pora).
Discussion
These analyses confirm that, while diverse, the VR1 and
VR2 peptide sequences can be assigned to distinct
meningococcal PorA variant sequence families. However,
these regions of the PorAprotein are likely to be exposed to
continual selection imposed by host immune responses, and
VR families might evolve over time into different families.
The similarity of the P1.2 and P1.10 VR2 families is per-
haps a consequence of relatively recent divergence of one
VR family into two. Devising a scheme for defining the
boundaries of VR families that accurately reflects the evo-
lution of these regions is therefore not possible. Moreover,
the high diversity of these sequences presents problems in
developing a facile nomenclature. In revising the nomen-
clature system, we used amino acid sequences, deduced
from nucleotide sequences, of the two VRs as the definition
of subtype variants. The replacement of letters with num-
bers in subtype variant designations overcomes the short-
age of letters but entails a change of name of variants. 
Since MAbs are still routinely used globally for
meningococcal serosubtyping, to avoid confusion, family
names from the previous nomenclature were retained
when possible, and especially when the family prototype
was specifically recognized by a typing MAb. The new
nomenclature builds on the previous designations but has
the advantage of a limitless capacity for expanding the
number of variants included. Retaining family names,
when they can be shown to be reasonable, results in some
minor changes to some family groupings. As meningococ-
ci evolve, the use of nucleotide sequencing to determine
the VR peptide sequences will be increasingly important
for epidemiologic studies and vaccine design, especially as
the MAb panel gradually becomes less useful and sequenc-
ing technology becomes more available.
In the course of this study, a number of VR sequences
that had been deposited previously in GenBank were found,
when resequenced, to contain errors and were in fact previ-
ously identified variants. These sequences had been given
new variant names and, in two cases, were sufficiently
novel to warrant the naming of new families. The wide-
spread use and, more importantly, the comparison of VR
sequence data among different laboratories require consis-
tency of nomenclature and a high level of data accuracy.
One way to achieve this is through a central PorA database
in which sequence electropherograms are submitted for
verification before new variant numbers are assigned. We
have established a Web site for this role (available from:
http://neisseria.org/nm/typing/pora). All known variants are
listed, and a database query page is provided so that a VR
sequence can be typed or pasted in and identified if previ-
ously seen. The Web site also includes links to the porB
typing and MLST Web pages. The PorAWeb site is now in
widespread use by the research community and provides a
single point of focus to ensure consistency in identifying
and naming this important protein.
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